Related references
Note: Only part of the references are listed.Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate
Roy Fleischmann et al.
ARTHRITIS CARE & RESEARCH (2020)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis
Young Ho Lee et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2020)
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: amatching-adjusted indirect comparison
B. Fautrel et al.
RMD OPEN (2020)
The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: a narrative review
Gurjit S. Kaeley et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Peter C. Taylor
RHEUMATOLOGY (2019)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen et al.
JOURNAL OF RHEUMATOLOGY (2019)
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials
Wenhui Xie et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
Josef S. Smolen et al.
LANCET (2019)
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
Roy M. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
Mark C. Genovese et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
Peter C. Taylor et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
Bruno Fautrel et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Clinical significance of Janus Kinase inhibitor selectivity
Ernest H. Choy
RHEUMATOLOGY (2019)
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Peter C. Taylor et al.
ARTHRITIS & RHEUMATOLOGY (2019)
EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Juergen Wollenhaupt et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach
Sarita Koride et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2019)
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies
Jean-Jacques Kiladjian et al.
ANNALS OF HEMATOLOGY (2018)
MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank
Xue Li et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Mark C. Genovese et al.
LANCET (2018)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Mark C. Genovese et al.
RHEUMATOLOGY (2018)
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
Bruno Fautrel et al.
RHEUMATOLOGY INTERNATIONAL (2018)
Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway
Fausto Salaffi et al.
PAIN RESEARCH & MANAGEMENT (2018)
The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black
Roy Fleischmann
ARTHRITIS & RHEUMATOLOGY (2018)
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Desiree van der Heijde et al.
CLINICAL RHEUMATOLOGY (2018)
A Novel Homozygous JAK3 Mutation Leading to T-B+NK- SCID in Two Brazilian Patients
Lucila A. Barreiros et al.
FRONTIERS IN PEDIATRICS (2018)
Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism
Momoko Chikugo et al.
JOURNAL OF MEDICAL INVESTIGATION (2018)
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
A. Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
R. Fleischmann et al.
CLINICAL RHEUMATOLOGY (2017)
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Roy Fleischmann et al.
LANCET (2017)
JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms
Jennifer M. O'Sullivan et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
Jose Ramon Maneiro et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey
S. Rifbjerg-Madsen et al.
PLOS ONE (2017)
Direct targets of pSTAT5 signalling in erythropoiesis
Kevin R. Gillinder et al.
PLOS ONE (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
Janus kinase inhibitors for rheumatoid arthritis
Kunihiro Yamaoka
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka et al.
JOURNAL OF RHEUMATOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
Peter C. Taylor et al.
RHEUMATOLOGY INTERNATIONAL (2016)
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
Christina Charles-Schoeman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
Vibeke Strand et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome
Mark J. Kiel et al.
NATURE COMMUNICATIONS (2015)
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
White-to-brown metabolic conversion of human adipocytes by JAK inhibition
Annie Moisan et al.
NATURE CELL BIOLOGY (2015)
THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis
V. Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an anchor drug?
Ennio Giulio Favalli et al.
AUTOIMMUNITY REVIEWS (2014)
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation
Rodolphe Besancenot et al.
BLOOD (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis
Lisa M. Lundquist et al.
WORLD JOURNAL OF ORTHOPEDICS (2014)
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market
Ken Garber
NATURE BIOTECHNOLOGY (2013)
MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer
John J. O'Shea et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease
Krzysztof Sikorski et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2011)
Management of chronic pain in the rheumatic diseases with insights for the clinician
Mary-Ann Fitzcharles et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2011)
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency
Yoshiyuki Minegishi et al.
INTERNATIONAL IMMUNOLOGY (2009)
The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom
Allison L. Smitten et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses
D Aletaha et al.
RHEUMATOLOGY (2002)
Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority
T Heiberg et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Share Paper
